Filtered By:
Condition: Pain
Management: Funding
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 29 results found since Jan 2013.
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study
Publication date: January 2017 Source:The Lancet Psychiatry, Volume 4, Issue 1 Author(s): Jong S Kim, Eun-Jae Lee, Dae-Il Chang, Jong-Ho Park, Seong Hwan Ahn, Jae-Kwan Cha, Ji Hoe Heo, Sung-Il Sohn, Byung-Chul Lee, Dong-Eog Kim, Hahn Young Kim, Seongheon Kim, Do-Young Kwon, Jei Kim, Woo-Keun Seo, Jun Lee, Sang-Won Park, Seong-Ho Koh, Jin Young Kim, Smi Choi-Kwon Background Mood and emotional disturbances are common in patients with stroke, and adversely affect the clinical outcome. We aimed to evaluate the efficacy of early administration of escitalopram to reduce moderate or severe depressive symptoms and improve emotion...
Source: The Lancet Psychiatry - December 21, 2016 Category: Psychiatry Source Type: research
Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial
This study is registered with ClinicalTrials.gov, number NCT01313299. Findings 243 patients were randomly allocated to placebo (n=81), abobotulinumtoxinA 500 U (n=81), or abobotulinumtoxinA 1000 U (n=81). Mean change in MAS score from baseline at week 4 in the PTMG was −0·3 (SD 0·6) in the placebo group (n=79), −1·2 (1·0) in the abobotulinumtoxinA 500 U group (n=80; difference −0·9, 95% CI −1·2 to −0·6; p<0·0001 vs placebo), and −1·4 (1·1) in the abobotulinumtoxinA 1000 U group (n=79; −1·1, −1·4 to −0·8; p<0·0001 vs placebo). Mean PGA score at week 4 was 0·6 (SD 1·0) in the ...
Source: The Lancet Neurology - August 27, 2015 Category: Neurology Source Type: research
Letter to the Editor: Pneumocephalus: Is the needle size significant?
Discussion. Pneumocephalus is defined by two mechanisms: a ball-valve and an inverted bottle concept.1 The ball-valve type implies positive pressure events, such as coughing or valsalva maneuvers, that prevent air escape. Tension pneumocephalus is included in this mechanism, causing a parenchymal mass effect. The inverted bottle theory includes a negative intracranial pressure gradient following cerebrospinal fluid drainage, relieved by air influx. A small pneumocephalus is usually sealed by blood clots or granulation, allowing spontaneous reabsorption and resolution.[1] Otherwise, the lateral positioning of a patient duri...
Source: Innovations in Clinical Neuroscience - February 1, 2018 Category: Neuroscience Authors: ICN Online Editor Tags: Assessment Tools CNS Infections Current Issue Letters to the Editor Neurologic Systems and Symptoms Neurology Stroke Traumatic Brain Injury epidural needle size Pneumocephalus spinal tap Source Type: research
Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial
Publication date: Available online 12 February 2015 Source:The Lancet Neurology Background Extracranial carotid and vertebral artery dissection is an important cause of stroke, especially in young people. In some observational studies it has been associated with a high risk of recurrent stroke. Both antiplatelet drugs and anticoagulant drugs are used to reduce risk of stroke but whether one treatment strategy is more effective than the other is unknown. We compared their efficacy in the Cervical Artery Dissection in Stroke Study (CADISS), with the additional aim of establishing the true risk of recurrent stroke. Methods W...
Source: The Lancet Neurology - February 13, 2015 Category: Neurology Source Type: research
On National Wear Red Day, Let's Empower Women To Know Their Numbers To Help Reduce Heart Disease
Today is National Wear Red Day, an opportunity to splash this vibrant color into your wardrobe as a declaration of your support for women with heart disease and stroke.
Doing so will link you in solidarity with Americans everywhere, including TV personalities across the networks and around the country. The tribute even extends to buildings and landmarks that will be bathed in red light.
We hope each glimpse is a reminder of the toll that heart disease takes, not just on the victims but also on the survivors left without a mother or a daughter, a wife or a friend, a colleague or a neighbor, or any other key roles in our liv...
Source: Healthy Living - The Huffington Post - February 3, 2017 Category: Consumer Health News Source Type: news
New Partnership Forms to Develop Breakthrough Neuromodulation Device
WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device.
The new MyoRegulator PM-200 provides a non-invasive treatment option for patients suffering from muscle spasticity, a common condition found in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury, and traumatic...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Kristopher Sturgis Tags: Business Source Type: news
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
This study is registered with ClinicalTrials.gov, number NCT01425307. Findings Between Sept 20, 2011, and April 17, 2013, 159 patients consented and enrolled in TWiTCH. 121 participants passed screening and were then randomly assigned to treatment (61 to transfusions and 60 to hydroxycarbamide). At the first scheduled interim analysis, non-inferiority was shown and the sponsor terminated the study. Final model-based TCD velocities were 143 cm/s (95% CI 140–146) in children who received standard transfusions and 138 cm/s (135–142) in those who received hydroxycarbamide, with a difference of 4·54 (0·10–8·98). Non-i...
Source: The Lancet - December 7, 2015 Category: Journals (General) Source Type: research
A Review of Mathematical Models for Muscular Dystrophy: A Systems Biology Approach
Discussion
With new developments in computational power and data availability, a growing amount of research is using a systems biology approach to understand pathogenesis and progression of disease. Effective and integrated in vitro and in silico models could inform biological phenomena, even without the need of a living subject. For instance, over the last few decades, collagen hydrogel with muscle derived cells (CHMDCs) have promised to revolutionize in vitro experiments and tissue engineering. For CHMDCs to reach the envisioned use, verification by use of mathematical simulations are needed. Recently while examining sha...
Source: PLOS Currents Muscular Dystrophy - February 16, 2018 Category: Neurology Authors: Matthew Houston Source Type: research
157 E-Books New to JEFFLINE
Scott Library added these 157 e-books to the growing collection in May and June:
Accurate Results in the Clinical Laboratory
Adult Emergency Medicine
Adult-Gerontology and Family Nurse Practitioner Certification Examination (4th ed.)
Advanced Assessment: Interpreting Findings and Formulating Differential Diagnoses (2nd ed.)
Advancing Your Career: Concepts of Professional Nursing (5th ed.)
Arrhythmia Essentials
Atlas of Advanced Operative Surgery
Atlas of Clinical Neurology (3rd ed.)
Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches
Atlas of Human Infectious Diseases
Atlas of No...
Source: What's New on JEFFLINE - June 25, 2013 Category: Databases & Libraries Authors: Gary Kaplan Tags: All News Clinicians Researchers Students Teaching Faculty Source Type: news
MicroTransponder completes $3.4M in funding, gets key patent
Dallas-based MicroTransponder Inc., a privately-held medical device company, has completed a $3.39 million funding round this summer, which will enable the company to accelerate development of its wireless pain platform.
The funding will allow MicroTransponder to complete three additional clinical trials using its neurostimulation system to treat both stroke patients and tinnitus patients, Jordan Curnes, co-founder, president and chief operating officer, told me.
Tinnitus is the medical term for…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 30, 2013 Category: Pharmaceuticals Authors: Bill Hethcock Source Type: research
NICE: 'Obese should be prescribed slimming clubs'
“GPs told to prescribe £100 slimming courses for millions of obese patients,” the Daily Mail reports.
The news is based on new guidelines from the National Institute for Health and Care Excellence (NICE) that aim to encourage sustainable weight loss in the obese; “lose a little, and keep it off”.
The guidance is mainly aimed at commissioners (who plan and agree which services will be provided in the NHS and monitor them), health professionals and groups who provide lifestyle weight management programmes. The recommendations may also be of interest to members of the public, including people who are overweight or o...
Source: NHS News Feed - May 28, 2014 Category: Consumer Health News Tags: Lifestyle/exercise Food/diet Obesity QA articles Source Type: news
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research
Be Aware and Beware: Chronic Fatigue Syndrome Is an Equal Opportunity Disease
Chronic Fatigue Syndrome, or CFS, is an innocuous name given to a debilitating disease. Its seriousness is better indicated by the term Myalgic Encephalomyelitis (ME), a label preferred by many of its victims. On May 17-18, the Department of Health and Human Services hosted the biannual public meeting of the Chronic Fatigue Syndrome Advisory Committee by webinar. This was a fitting time for such a meeting, as May is International ME/CFS Awareness Month.
The trigger for CFS/ME is not known. The lack of research on the disease means there is no truly effective and widely available therapy that would allow the more serious...
Source: Healthy Living - The Huffington Post - May 20, 2016 Category: Consumer Health News Source Type: news
Fatigue in rheumatoid arthritis 'may need to be treated separately'
This study highlights the need for better treatments for fatigue, which can be used alongside existing medication. We need to ensure fatigue has recognition from medical professionals so people can get the care they require."Along with pain, fatigue is one of the things that people with arthritis tell us has the biggest impact on their lives, which is why Arthritis Research UK is funding research into coping with the effects of fatigue on a day-to-day basis."
Source: Arthritis Research UK - June 23, 2016 Category: Rheumatology Source Type: news
